Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen 
Welcome,         Profile    Billing    Logout  
 11 Diseases   24 Trials   24 Trials   1081 News 


«12345678910111213...1314»
  • ||||||||||  DR (Convention Center Exhibit Hall) -  Aug 4, 2023 - Abstract #CHEST2023CHEST_922;    
  • ||||||||||  Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
    Review, Journal:  Efficacy and Potential Positioning of Tezepelumab in the Treatment of Severe Asthma. (Pubmed Central) -  Jul 27, 2023   
    Six clinical trials that included 2187 patients with uncontrolled asthma, with 2 or more exacerbations in the previous year, on medium/high-dose inhaled corticosteroids and at least 1 other controller, have demonstrated - irrespective of T2 endotype (and possibly also non-T2 endotype) - the efficacy and safety of tezepelumab, as it significantly reduces exacerbations (61.7%-66%) and bronchial hyperresponsiveness, and improves lung function, disease control, and quality of life. Tezepelumab could be indicated for the treatment of patients with, independently of the T2 phenotype (eosinophilic and non-eosinophilic), and may even be the only biologic available for treatment of non-T2 SUCA.
  • ||||||||||  Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
    Journal, HEOR, Cost-effectiveness, Cost effectiveness:  Cost-effectiveness of tezepelumab in Canada for severe asthma. (Pubmed Central) -  Jul 19, 2023   
    P3
    Tezepelumab provided additional life years and QALYs at additional cost compared with SoC in Canada. In addition, tezepelumab dominated (i.e., more effective, less costly) the other currently reimbursed biologics.
  • ||||||||||  Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
    Preclinical, Journal:  An overview of the preclinical discovery and development of tezepelumab for the treatment of asthma. (Pubmed Central) -  Jun 30, 2023   
    Furthermore, it appears to be a safe drug and can be 'self-administered' using a pre-filled, disposable pen. Tezepelumab should be preferred over other currently available biologics because blocking upstream mediators may have a broader therapeutic impact than those that inhibit downstream cytokines and/or block their receptors.
  • ||||||||||  Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
    New trial:  TezepelumabPRO: Tezepelumab PRO Study (clinicaltrials.gov) -  Jun 28, 2023   
    P=N/A,  N=90, Not yet recruiting, 
  • ||||||||||  Journal:  Biologics for the treatment of severe asthma: Current status report 2023 (Pubmed Central) -  Jun 26, 2023   
    Existing studies have shown that all the approved biologic agents targeting cells, receptors, and mediators involved in type 2 inflammation in the bronchial wall in severe asthma significantly reduce asthma exacerbations, reduce the need for oral corticosteroids, and improve asthma control, quality of life, and pulmonary functions. Characterizing the asthma endotype and phenotype in patients with severe asthma and determining which treatment would be more appropriate for a particular patient is an essential step in personalized treatment.
  • ||||||||||  Dupixent (dupilumab) / Sanofi, Regeneron, Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
    Review, Journal:  Efficacy of Biologics in Severe, Uncontrolled Asthma Stratified by Blood Eosinophil Count: A Systematic Review. (Pubmed Central) -  Jun 19, 2023   
    Characterizing the asthma endotype and phenotype in patients with severe asthma and determining which treatment would be more appropriate for a particular patient is an essential step in personalized treatment. The efficacy of all biologics in reducing AAER in patients with severe asthma increases with higher baseline BEC, with varying profiles across individual biologics likely due to differing mechanisms of action.
  • ||||||||||  Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
    Long-term safety and efficacy of tezepelumab in adolescents with severe, uncontrolled asthma (PS-7 in poster area) -  Jun 17, 2023 - Abstract #ERS2023ERS_4379;    
    Cell and molecular biology; Public health; General respiratory patient care; Epidemiology; Pulmonary function testing Cell and molecular biology; Public health; General respiratory patient care; Epidemiology; Pulmonary function testing
  • ||||||||||  Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
    Tezepelumab can restore normal lung function in patients with severe, uncontrolled asthma (Red 1+2) -  Jun 17, 2023 - Abstract #ERS2023ERS_1373;    
    Cell and molecular biology; Endoscopy and interventional pulmonology; General respiratory patient care; Physiology Cell and molecular biology; Endoscopy and interventional pulmonology; General respiratory patient care; Physiology
  • ||||||||||  Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
    Enrollment closed:  DIRECTION: Study to Evaluate Tezepelumab in Adults With Severe Uncontrolled Asthma (clinicaltrials.gov) -  May 16, 2023   
    P3,  N=386, Active, not recruiting, 
    Tezepelumab significantly decreased biomarkers of T helper 2-driven inflammation, including blood eosinophil count (MD -135.8 [95% CI -164.37, -107.23]) and fractional exhaled nitric oxide (MD -9.64 [95% CI -13.75, -5.53]); improved PFTs, including pre-bronchodilator forced expiratory volume in 1 Recruiting --> Active, not recruiting
  • ||||||||||  Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
    Journal:  TSLP-targeting therapy: Beyond allergy? (Pubmed Central) -  May 15, 2023   
    Recruiting --> Active, not recruiting No abstract available
  • ||||||||||  Review, Journal:  "The Evolving Landscape of Immunotherapy for the Treatment of Allergic Conditions". (Pubmed Central) -  May 12, 2023   
    As biologics become more targeted, fewer off-target effects are seen improving tolerability for patients as well as expanded options for treatment of these conditions. This review discusses monoclonal antibody therapies (omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab, tezepelumab, tralokinumab) including their safety and use in asthma, chronic urticaria, atopic dermatitis, and eosinophilic esophagitis.
  • ||||||||||  Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
    Review, Journal:  Severe Asthmatic Responses: The Impact of TSLP. (Pubmed Central) -  May 2, 2023   
    Undoubtedly, the magnitude of TSLP in asthma pathogenesis is highlighted by the fact that the FDA recently approved tezepelumab (Tezspire), a human monoclonal antibody that targets TSLP, for SA treatment. Nevertheless, further research focusing on the biology and mode of function of TSLP in SA will considerably advance disease management.
  • ||||||||||  Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
    Efficacy of tezepelumab in patients with perennial allergy grouped by specific immunoglobulin E thresholds and by age (Hall Y 03+04) -  Apr 30, 2023 - Abstract #EAACI2023EAACI_782;    
    P2, P3
    When assessing a higher threshold of sensitivity, 64% (138/215) of patients aged <35 years old had ?1 specific perennial IgE level ?17.5 kUA/L versus 26% (296/1119) of those aged ?35 years old. In both age groups, reductions in AAERs over 52 weeks with tezepelumab versus placebo were similar across all specific IgE threshold subgroups (Figure).
  • ||||||||||  Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
    Enrollment open:  TEZSPIRE (Tezepelumab) Asthma Japan Post-Marketing Study (PMS) (clinicaltrials.gov) -  Apr 13, 2023   
    P=N/A,  N=400, Recruiting, 
    These findings further support the benefits of tezepelumab in a broad population of patients with severe asthma, including those with severe allergic asthma. Not yet recruiting --> Recruiting
  • ||||||||||  Journal:  Eosinophilic respiratory disorders and the impact of biologics. (Pubmed Central) -  Mar 31, 2023   
    Not yet recruiting --> Recruiting Insight into the biology of eosinophilic respiratory diseases has been critical for understanding disease pathogenesis and has contributed to the development of effective eosinophil-targeted biologic interventions.
  • ||||||||||  Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
    Enrollment open:  REVERT: REVErsing Airway Remodelling With Tezepelumab (clinicaltrials.gov) -  Mar 29, 2023   
    P3,  N=90, Recruiting, 
    Insight into the biology of eosinophilic respiratory diseases has been critical for understanding disease pathogenesis and has contributed to the development of effective eosinophil-targeted biologic interventions. Not yet recruiting --> Recruiting
  • ||||||||||  Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
    TEZSPIRE (Grand Hyatt Washington; Theater 1) -  Mar 25, 2023 - Abstract #ATS2023ATS_8808;    
    Sponsored By Amgen/AstraZeneca Please join Amgen and AstraZeneca for an expert-led presentation that may shift your perspective. Our experts will share the efficacy and safety data around a different approach.
  • ||||||||||  Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen
    Efficacy of Tezepelumab in Patients With Severe, Uncontrolled Asthma by Sex: Results From the Phase 3 Navigator Study (Walter E. Washington Convention Center, Area F, Hall C (Lower Level)) -  Mar 25, 2023 - Abstract #ATS2023ATS_7422;    
    P3
    Tezepelumab reduced exacerbations and improved lung function, asthma control and HRQoL versus placebo to similar degrees in male and female patients. These results further support the efficacy of tezepelumab in a broad population of patients with severe, uncontrolled asthma.
  • ||||||||||  Tezspire (tezepelumab-ekko) / AstraZeneca, Amgen, IMG-036 / Inmagene
    Enhanced Blocking toward TSLP Variants at Lung Barrier Protects against Experimental Asthma (Walter E. Washington Convention Center, Area G, Hall C (Lower Level)) -  Mar 25, 2023 - Abstract #ATS2023ATS_6070;    
    IMG-036 exhibited strong TSLP blocking from in vitro assays and protected against experimental asthma in vivo. The characterization of blocking TSLP variants and penetrating lung barrier is likely to transform into enhanced blocking potential under inflammatory conditions like asthma.